With a view to a potential launch of intravenous iclaprim in 2008, we are significantly expanding our medical and scientific communications. A total of 24 abstracts on iclaprim have been accepted at the upcoming ICAAC and IDSA conferences in the USA. We are eager to share our preclinical and clinical data with the medical and scientific community.
Dr Islam added: Progress was not limited to our most advanced programme, but was seen across the board. It included the authorisation from the US FDA to initiate Phase II trials with intravenous iclaprim in hospital-acquired pneumonia, as well as steady progress in other programmes such as oral iclaprim, AR-709 and AR-2474. Looking at the disturbing increase and the broadening of bacterial resistance against many of the current drugs, I feel these antibiotic programmes are aimed at significant existing or emerging medical needs.
Very recently, we succeeded in broadening our clinical pipeline further by acquiring the late-stage anti-fungal TLT therapy. TLT is about to enter Phase III clinical trials in Europe targeting onychomycosis an important indication, affecting dozens of millions of people worldwide.
Dr Islam concluded: Overall I can say that Arpida remains on a steady, successful course, strengthening the foundations for a profitable future.
Financial review for six months to 30 June 2007
Key financial indicators
(CHF million) 2007 H1 2006 H2 2006 H1
Research and development expenses (27.7) (40.8) (23.9)
Management and general expenses (6.0) (4.6) (4.6)
Total operating expenses (33.7) (45.4) (28.5)
Net result (33.8) (44.6) (27.9)
Cash and financial investments end of 94.7 72.8 98.6
Equity end of period 87.7 65.5 104.9
Copyright©2007 PR Newswire.
All rights reserved